Insurers should screen older smokers for lung cancer

Share this article:
Insurers Should Screen Older Smokers for Lung Cancer
Insurers Should Screen Older Smokers for Lung Cancer

(HealthDay News) -- Lung cancer screening with low-dose spiral computed tomography could be of substantial value in high-risk smoker populations over the age of 50, and commercial insurers should consider providing coverage for the screening, according to a study published in the April issue of Health Affairs.

Bruce S. Pyenson, from the actuarial and consulting firm Milliman in New York City, and colleagues used actuarial models to evaluate the costs and benefits of offering annual lung cancer screening as a commercial insurance benefit in the high-risk U.S. population (ages 50 to 64 years). Current commercial reimbursement rates for treatment were used.

The researchers found that the cost of screening would be about $1 per month in 2012 dollars for each insured member. The cost per life-year saved would be less than $19,000, which is comparable with screening costs for cervical, breast, and colorectal cancers.

"Our results suggest that commercial insurers should consider lung cancer screening of high-risk individuals to be high-value coverage and provide it as a benefit to people who are at least 50 years old and have a smoking history of thirty pack-years or more," the authors write.

One of the authors holds patents related to lung cancer care; these patents do not involve the use of low-dose spiral computed tomography.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.